Bispecific antibody study for B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at a type of treatment called a bispecific antibody for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It aims to learn how well this treatment works in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with B-cell non-Hodgkin lymphoma
- Your lymphoma has returned or not responded after at least one prior treatment
- You are scheduled to receive a CD20xCD3 bispecific antibody as part of your treatment plan
- You have signed a consent form for this investigational treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called glofitamab (a type of immunotherapy) given as a follow-up treatment after initial therapy for people with high-risk large B-cell lymphoma. The goal is to see if it helps keep the cancer from coming back.
This study is looking at how well the drug glofitamab works in people whose diffuse large B-cell lymphoma (a common type of lymphoma) didn't respond to, or came back quickly after, their first therapy. The goal is to learn how effective and safe glofitamab is in the real world when it is added to standard care.
This study is testing how well the drug Glofitamab works when given along with standard rescue treatments for adults with B-cell Non-Hodgkin Lymphoma that has relapsed or not responded to prior therapy. The goal is to see if this combination is effective and safe in everyday medical practice.
This trial tests a drug called glofitamab, which helps your immune system attack lymphoma cells. It is for people with aggressive B-cell lymphoma that has grown after standard treatments. The study uses a biopsy to tailor the treatment during therapy.
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
This trial tests the drug glofitamab given before or after a stem cell transplant for patients whose B-cell lymphoma has returned or not improved. It aims to see if glofitamab can help make the transplant more effective or prevent the cancer from coming back.
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.